S&P 500   4,651.64 (+1.24%)
DOW   35,097.40 (+0.57%)
QQQ   398.42 (+1.85%)
AAPL   160.07 (+2.08%)
MSFT   337.15 (+2.27%)
FB   337.46 (+1.30%)
GOOGL   2,900.15 (+1.99%)
AMZN   3,578.19 (+2.10%)
TSLA   1,132.11 (+4.64%)
NVDA   327.48 (+3.95%)
BABA   131.69 (-1.24%)
NIO   39.80 (-0.48%)
CGC   11.04 (-5.56%)
AMD   158.91 (+2.65%)
GE   97.35 (-0.50%)
MU   84.52 (+1.32%)
T   23.92 (-1.24%)
F   19.67 (-0.41%)
DIS   144.87 (-2.19%)
ACB   6.42 (-5.45%)
AMC   36.27 (-3.61%)
PFE   53.96 (-0.07%)
BA   196.50 (-1.36%)
S&P 500   4,651.64 (+1.24%)
DOW   35,097.40 (+0.57%)
QQQ   398.42 (+1.85%)
AAPL   160.07 (+2.08%)
MSFT   337.15 (+2.27%)
FB   337.46 (+1.30%)
GOOGL   2,900.15 (+1.99%)
AMZN   3,578.19 (+2.10%)
TSLA   1,132.11 (+4.64%)
NVDA   327.48 (+3.95%)
BABA   131.69 (-1.24%)
NIO   39.80 (-0.48%)
CGC   11.04 (-5.56%)
AMD   158.91 (+2.65%)
GE   97.35 (-0.50%)
MU   84.52 (+1.32%)
T   23.92 (-1.24%)
F   19.67 (-0.41%)
DIS   144.87 (-2.19%)
ACB   6.42 (-5.45%)
AMC   36.27 (-3.61%)
PFE   53.96 (-0.07%)
BA   196.50 (-1.36%)
S&P 500   4,651.64 (+1.24%)
DOW   35,097.40 (+0.57%)
QQQ   398.42 (+1.85%)
AAPL   160.07 (+2.08%)
MSFT   337.15 (+2.27%)
FB   337.46 (+1.30%)
GOOGL   2,900.15 (+1.99%)
AMZN   3,578.19 (+2.10%)
TSLA   1,132.11 (+4.64%)
NVDA   327.48 (+3.95%)
BABA   131.69 (-1.24%)
NIO   39.80 (-0.48%)
CGC   11.04 (-5.56%)
AMD   158.91 (+2.65%)
GE   97.35 (-0.50%)
MU   84.52 (+1.32%)
T   23.92 (-1.24%)
F   19.67 (-0.41%)
DIS   144.87 (-2.19%)
ACB   6.42 (-5.45%)
AMC   36.27 (-3.61%)
PFE   53.96 (-0.07%)
BA   196.50 (-1.36%)
S&P 500   4,651.64 (+1.24%)
DOW   35,097.40 (+0.57%)
QQQ   398.42 (+1.85%)
AAPL   160.07 (+2.08%)
MSFT   337.15 (+2.27%)
FB   337.46 (+1.30%)
GOOGL   2,900.15 (+1.99%)
AMZN   3,578.19 (+2.10%)
TSLA   1,132.11 (+4.64%)
NVDA   327.48 (+3.95%)
BABA   131.69 (-1.24%)
NIO   39.80 (-0.48%)
CGC   11.04 (-5.56%)
AMD   158.91 (+2.65%)
GE   97.35 (-0.50%)
MU   84.52 (+1.32%)
T   23.92 (-1.24%)
F   19.67 (-0.41%)
DIS   144.87 (-2.19%)
ACB   6.42 (-5.45%)
AMC   36.27 (-3.61%)
PFE   53.96 (-0.07%)
BA   196.50 (-1.36%)
NASDAQ:ALDX

Aldeyra Therapeutics Stock Forecast, Price & News

$7.34
-0.34 (-4.43%)
(As of 11/29/2021 11:45 AM ET)
Add
Compare
Today's Range
$7.15
$7.75
50-Day Range
$7.68
$9.63
52-Week Range
$6.47
$15.95
Volume
26,102 shs
Average Volume
1.26 million shs
Market Capitalization
$426.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
30 days | 90 days | 365 days | Advanced Chart
Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Aldeyra Therapeutics logo

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.78 per share

Profitability

Net Income
$-37.55 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
54,084,000
Market Cap
$426.40 million
Optionable
Optionable

Company Calendar

Last Earnings
10/27/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.99 out of 5 stars

Medical Sector

619th out of 1,392 stocks

Pharmaceutical Preparations Industry

286th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

Is Aldeyra Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aldeyra Therapeutics stock.
View analyst ratings for Aldeyra Therapeutics
or view top-rated stocks.

How has Aldeyra Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALDX stock has increased by 163.1% and is now trading at $7.34.
View which stocks have been most impacted by COVID-19
.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Aldeyra Therapeutics
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.26) by $0.01. During the same quarter last year, the business posted ($0.23) earnings per share.
View Aldeyra Therapeutics' earnings history
.

What price target have analysts set for ALDX?

3 brokers have issued 12-month price objectives for Aldeyra Therapeutics' shares. Their forecasts range from $22.00 to $32.00. On average, they anticipate Aldeyra Therapeutics' stock price to reach $26.25 in the next twelve months. This suggests a possible upside of 257.6% from the stock's current price.
View analysts' price targets for Aldeyra Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the following people:
  • Todd C. Brady, M.D., Ph.D., Chief Executive Officer and Director (Age 48)
  • Joshua Reed, Chief Financial Officer (Age 47)
  • David McMullin, Chief Commercial Officer (Age 45)
  • James A. Gow, M.D., Senior Vice President of Clinical Development (Age 53)
  • Stephen G. Machatha, Ph.D., Senior Vice President, Technical Operation (Age 43)

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.62%), Eagle Asset Management Inc. (2.32%), Geode Capital Management LLC (1.55%), Two Sigma Investments LP (1.37%), Two Sigma Advisers LP (1.36%) and Prosight Management LP (1.27%). Company insiders that own Aldeyra Therapeutics stock include Life Sciences Maste Perceptive, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends for Aldeyra Therapeutics
.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Two Sigma Investments LP, Two Sigma Advisers LP, Citadel Advisors LLC, First Midwest Bank Trust Division, Citigroup Inc., and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Aldeyra Therapeutics
or view top insider-selling stocks.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was purchased by a variety of institutional investors in the last quarter, including Johnson & Johnson, HealthInvest Partners AB, Eagle Asset Management Inc., Prosight Management LP, UBS Group AG, Caption Management LLC, Jetstream Capital LLC, and GSA Capital Partners LLP. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Perceptive Advisors Llc, Richard Douglas, and Todd C Brady.
View insider buying and selling activity for Aldeyra Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $7.34.

How much money does Aldeyra Therapeutics make?

Aldeyra Therapeutics has a market capitalization of $426.40 million. The biotechnology company earns $-37.55 million in net income (profit) each year or ($1.15) on an earnings per share basis.

How many employees does Aldeyra Therapeutics have?

Aldeyra Therapeutics employs 15 workers across the globe.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is www.ampliphibio.com.

Where are Aldeyra Therapeutics' headquarters?

Aldeyra Therapeutics is headquartered at 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904, via email at [email protected], or via fax at 781-270-0630.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.